• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.

作者信息

Li B, Zhang P, Feng G, Xu Z, Qin T, Zhang Y, Sha Z, Dong D, Zhang H, Fang L, Pan L, Hu N, Qu S, Cai W, Huang G, Xiao Z

机构信息

MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

出版信息

Blood Cancer J. 2016 Dec 9;6(12):e505. doi: 10.1038/bcj.2016.116.

DOI:10.1038/bcj.2016.116
PMID:27935577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5223151/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a52/5223151/dc671fe11d85/bcj2016116f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a52/5223151/dc671fe11d85/bcj2016116f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a52/5223151/dc671fe11d85/bcj2016116f1.jpg

相似文献

1
Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.骨髓纤维化分级是原发性骨髓纤维化患者总生存期的独立危险因素。
Blood Cancer J. 2016 Dec 9;6(12):e505. doi: 10.1038/bcj.2016.116.
2
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.原发性血小板增多症和原发性骨髓纤维化的突变状态决定临床结局。
Haematologica. 2016 Apr;101(4):e129-32. doi: 10.3324/haematol.2015.138958. Epub 2016 Jan 14.
3
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.一种由年龄、JAK2、CALR和MPL突变状态组成的用于原发性骨髓纤维化患者的准确、简单的预后模型。
Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.
4
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.整合临床、形态学和分子数据评估初诊原发性骨髓纤维化患者的预后：一种实用方法。
Hematol Oncol. 2019 Oct;37(4):424-433. doi: 10.1002/hon.2658. Epub 2019 Aug 22.
5
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.经典型骨髓增殖性肿瘤的诊断、风险分层及反应评估
Blood. 2017 Feb 9;129(6):680-692. doi: 10.1182/blood-2016-10-695957. Epub 2016 Dec 27.
6
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.莫洛替尼治疗的骨髓纤维化患者反应和生存的遗传决定因素。
Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.
7
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.CALR 突变、MPL 突变和三阴性可识别原发性骨髓纤维化中血管风险最低的患者。
Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8.
8
Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis.原发性骨髓纤维化患者中I型CALR与两个MPL突变的共现。
Ann Hematol. 2017 Aug;96(8):1417-1418. doi: 10.1007/s00277-017-3022-x. Epub 2017 May 13.
9
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.原发性和继发性骨髓纤维化之间，驱动基因突变特异性的临床和基因组相关性存在差异。
Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10.
10
The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.胚系 JAK2 GGCC（46/1）单倍型与 414 例分子注释的原发性骨髓纤维化患者的生存。
Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

引用本文的文献

1
Folate metabolism in myelofibrosis: a missing key?骨髓纤维化中的叶酸代谢：一把缺失的钥匙？
Ann Hematol. 2025 Jan;104(1):35-46. doi: 10.1007/s00277-024-06176-y. Epub 2025 Jan 23.
2
Endothelial LATS2 is a suppressor of bone marrow fibrosis.内皮细胞的大肿瘤抑制激酶2是骨髓纤维化的一种抑制因子。
Nat Cardiovasc Res. 2024;3(8):951-969. doi: 10.1038/s44161-024-00508-x. Epub 2024 Jul 29.
3
Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms.中国 BCR::ABL1 阴性骨髓增殖性肿瘤患者髓系粒细胞的免疫表型。

本文引用的文献

1
The prognostic impact of bone marrow fibrosis in primary myelofibrosis.骨髓纤维化在原发性骨髓纤维化中的预后影响。
Am J Hematol. 2016 Oct;91(10):E454-5. doi: 10.1002/ajh.24482. Epub 2016 Jul 29.
2
The prognostic impact of bone marrow fibrosis in primary myelofibrosis.原发性骨髓纤维化中骨髓纤维化的预后影响。
Am J Hematol. 2016 Oct;91(10):E454. doi: 10.1002/ajh.24458. Epub 2016 Jul 14.
3
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.《世界卫生组织髓系增殖性肿瘤分类（2016年修订版）：临床与分子进展》
Clin Exp Med. 2024 May 21;24(1):106. doi: 10.1007/s10238-024-01363-7.
4
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.骨髓纤维化患者接受莫洛替尼或芦可替尼治疗期间，骨髓纤维化的变化与疗效结果无关。
EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. eCollection 2024 Feb.
5
Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia.马来西亚骨髓增殖性肿瘤患者的死亡率结果和生存模式。
Cancer Causes Control. 2022 Feb;33(2):343-351. doi: 10.1007/s10552-021-01521-2. Epub 2021 Nov 30.
6
The relationship between serum ferritin level and fibrosis and splenomegaly in myelofibrosis.骨髓纤维化中血清铁蛋白水平与纤维化及脾肿大的关系。
Am J Blood Res. 2020 Dec 15;10(6):345-350. eCollection 2020.
7
[Fibrosis-driving cells in patients with primary myelofibrosis and myelodysplastic syndromes with myelofibrosis].[原发性骨髓纤维化和骨髓增生异常综合征伴骨髓纤维化患者中驱动纤维化的细胞]
Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):1002-1007. doi: 10.3760/cma.j.issn.0253-2727.2020.12.006.
8
[Chinese guideline on the diagnosis and treatment of primary myelofibrosis (2019)].[原发性骨髓纤维化诊断与治疗中国指南（2019年版）]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jan 14;40(1):1-7. doi: 10.3760/cma.j.issn.0253-2727.2019.01.001.
9
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.费城染色体阴性骨髓增殖性肿瘤的预后评估：近期文献综述
Curr Hematol Malig Rep. 2017 Oct;12(5):397-405. doi: 10.1007/s11899-017-0401-2.
Blood Rev. 2016 Nov;30(6):453-459. doi: 10.1016/j.blre.2016.06.001. Epub 2016 Jun 11.
4
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.原发性骨髓纤维化中骨髓纤维化的预后影响。AGIMM 组对 490 例患者的研究。
Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4.
5
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
6
Calreticulin mutations in Chinese with primary myelofibrosis.中国原发性骨髓纤维化患者中钙网蛋白的突变
Haematologica. 2014 Nov;99(11):1697-700. doi: 10.3324/haematol.2014.109249. Epub 2014 Jul 4.
7
High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.骨髓增殖性肿瘤患者网状纤维纤维化和细胞密度分级具有高度一致性。
Mod Pathol. 2014 Nov;27(11):1447-54. doi: 10.1038/modpathol.2014.69. Epub 2014 Apr 25.
8
Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.关于世界卫生组织定义的早期/前纤维化原发性骨髓纤维化与特发性血小板增多症的诊断问题和陷阱。
Leukemia. 2013 Oct;27(10):1953-8. doi: 10.1038/leu.2013.74. Epub 2013 Mar 7.
9
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.年轻的原发性骨髓纤维化伴早期/纤维化前与特发性血小板增多症患者的疾病特征和临床结局。
Blood. 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. Epub 2012 Jun 13.
10
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.欧洲骨髓工作组关于世界卫生组织标准区分原发性骨髓纤维化伴前纤维化与特发性血小板增多症的可重复性的试验。
Haematologica. 2012 Mar;97(3):360-5. doi: 10.3324/haematol.2011.047811. Epub 2011 Nov 4.